Regulus Therapeutics Inc (NASDAQ:RGLS) currently has a daily average trading volume of 2.01M but it saw 744968 shares traded in last market. With a market cap of 549.03M USD, the company’s current market price of $7.93 came rising about 0.25 while comparing to the previous closing price of $7.91. In past 52 weeks, the stock remained buoying in the range of price level as high as $8.20 and as low as $0.83.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Wells Fargo which upgraded the stock as “Overweight” in its note to investors issued on March 27, 2025, recommending a price target of between $3 and $6 for it. Leerink Partners issued its recommendations for the stock as it initiated the price target for the stock is $6.
Over the week, RGLS’s stock price is moving -0.25% down while it is 127.22% when we observe its performance for the past one month. Year-to-date it is 401.90% up and over the past year, the stock is showing an upside performance of 313.02%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of -0.18 while estimate for next year EPS is -0.78.
Currently, Regulus Therapeutics Inc’s total number of outstanding shares is 66.28M with 2.69% of that held by the insiders while 82.87% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -67.48% and return on equity (ROE) at -53.82%. Stock’s beta reads 0.36. Stock has a price to book (P/B) ratio of 7.62. Its return on asset (ROA) is -50.30% on average.
